Dr. Paulovich has developed a new technology that couples peptide immuno-affinity enrichment with multiple reaction monitoring mass spectrometry (MRM). The end products are highly multiplex-able immuno-MRM assays that allow precise, specific quantification of proteins, providing a critical capability that relieves the bottleneck that has hindered the translation of novel diagnostics into clinical use. She hopes to apply this technology to characterize human phenotypic variation and to relate this variation to clinically relevant endpoints. Other projects in her laboratory focus on cancer biology, with a specific emphasis on using model systems and integrative ‘omics’ to predict biomarkers of human disease, especially targeting the DNA damage response.